Interleukin-1β Regulates Fat-Liver Crosstalk in Obesity by Auto-Paracrine Modulation of Adipose Tissue Inflammation and Expandability-Reference-Cited by-同舟云学术

Interleukin-1β Regulates Fat-Liver Crosstalk in Obesity by Auto-Paracrine Modulation of Adipose Tissue Inflammation and Expandability

Published:2013-01-16 Issue:1 Volume:8 Page:e53626
ISSN:1932-6203
Container-title:PLoS ONE
language:en
Short-container-title:PLoS ONE

Author:

Nov Ori,Shapiro Hagit,Ovadia Hilla,Tarnovscki Tanya,Dvir Irit,Shemesh Elad,Kovsan Julia,Shelef Ilan,Carmi Yaron,Voronov Elena,Apte Ron N.,Lewis Eli,Haim Yulia,Konrad Daniel,Bashan Nava,Rudich Assaf

Publisher

Public Library of Science (PLoS)

Subject

Multidisciplinary

Reference47 articles.

1. Adipose and liver expression of interleukin (IL)-1 family members in morbid obesity and effects of weight loss;AR Moschen;Mol Med,2011

2. The inflammasome puts obesity in the danger zone;R Stienstra;Cell Metab,2012

3. Inflammatory cytokines and the risk to develop type 2 diabetes: results of the prospective population-based European Prospective Investigation into Cancer and Nutrition (EPIC)-Potsdam Study;J Spranger;Diabetes,2003

4. Interleukin-1-receptor antagonist in type 2 diabetes mellitus;CM Larsen;N Engl J Med,2007

5. The NLRP3 inflammasome instigates obesity-induced inflammation and insulin resistance;B Vandanmagsar;Nat Med,2011

Cited by 128 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. IL-1β promotes adipogenesis by directly targeting adipocyte precursors;Nature Communications;2024-09-11

2. Sıçanlarda Yüksek Oranda Doymuş Yağlı Diyet ile Aralıklı Beslemenin Deneysel Kolon Kanseri Gelişimi ve Bazı Serum İnflamasyon Markırları Üzerine Etkisi;Van Sağlık Bilimleri Dergisi;2024-04-30

3. Innate Immunity and MASLD;Biomolecules;2024-04-13

4. The PD-1/PD-L1 Axis in the Biology of MASLD;International Journal of Molecular Sciences;2024-03-25

5. From Bench to Bedside: Implications of Lipid Nanoparticle Carrier Reactogenicity for Advancing Nucleic Acid Therapeutics;Pharmaceuticals;2023-07-31